Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cornelius Mance

Neurology Hixson, TN Medical Doctor

NPI 1861586331 CMS profile 265796

2051 Hamill Rd, Ste 302, Hixson, TN 37343

Open in the dashboard

General payments

$17,342

876 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cornelius Mance of Hixson, TN is reported in the CMS Open Payments database as having received $17,342 across 876 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,427 111
2024 General $2,509 122
2023 General $2,378 124
2022 General $2,241 116
2021 General $2,681 138
2020 General $2,064 102
2019 General $3,040 163

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cornelius Mance
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Cornelius Mance were reported at $2,427. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Cornelius Mance Neurology median Middle half National median
2019 $3,040 $474 $118–$2,177 $163
2020 $2,064 $367 $82–$2,309 $114
2021 $2,681 $438 $104–$2,547 $132
2022 $2,241 $442 $103–$2,388 $149
2023 $2,378 $464 $119–$2,312 $160
2024 $2,509 $468 $119–$2,323 $164
2025 $2,427 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $1,260 60 payments
  2. Amgen Inc. $1,180 35 payments
  3. Neurocrine Biosciences, Inc. $1,134 54 payments
  4. Biogen, Inc. $1,104 59 payments
  5. AbbVie, Inc. $894 62 payments
  6. UCB, Inc. $834 35 payments
  7. ACADIA Pharmaceuticals Inc $766 46 payments
  8. Lilly USA, LLC $731 34 payments
  9. Eisai Inc. $562 29 payments
  10. Novartis Pharmaceuticals Corporation $549 28 payments
  11. Other $8,328 434 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,230 872 payments
  2. Education $112 4 payments
Products named General payments · program years 2019–2025
  1. AIMOVIG $947 29 payments
  2. ZEPOSIA $676 37 payments
  3. QULIPTA $636 44 payments
  4. INGREZZA $634 32 payments
  5. Briviact $592 21 payments
  6. TYSABRI $583 30 payments
  7. UBRELVY $549 36 payments
  8. NUPLAZID $499 28 payments
  9. NURTEC ODT $497 27 payments
  10. NUEDEXTA $497 42 payments
  11. Other $12,253 618 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

1,455

Median for Internal Medicine: 777

Drug cost

$1,152,686

Median for Internal Medicine: $73,373

Branded share of claims

29.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xywav Sodium,calcium,mag,pot Oxybate Brand 12 $237,382
Austedo Deutetrabenazine Brand 12 $168,274
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 13 $145,894
Kesimpta Pen Ofatumumab Brand 13 $138,917
Aubagio Teriflunomide Brand 14 $128,631
Nuplazid Pimavanserin Tartrate Brand 17 $83,113
Briviact Brivaracetam Brand 41 $80,946
Fycompa Perampanel Brand 39 $48,669
Nuedexta Dextromethorphan Hbr/Quinidine Brand 25 $36,697
Emgality Pen Galcanezumab-Gnlm Brand 22 $14,510

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$85,779

Medicare's payments for the services billed

Medicare patients

413

Average age 76

Services billed

1,072

231 women, 182 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Diabetes 43%
Ischemic heart disease 42%
Chronic kidney disease 41%
Depression 36%
Heart failure 31%
Atrial fibrillation 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
$206 — —
VYVGART Hytrulo
$189 — —
ZEPOSIA
$168 — —
NUPLAZID
$152 17 —
UBRELVY
$149 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

876 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record